- NewsCategory：
- All Company news Industry news
common105One result
-
1018
HitGen Enters into DNA-Encoded Libr>&"$ary Based Drug Discovery↔β♦ Research Collaboration with Galapagos ♦ NV
HitGen Enters into DNA-Encoded Libra™δry Based Drug Discovery Res™σφearch Collaboration with Galapa×♣✘gos NVTHURSDAY, OCTOBER 17, 2≤♠019HitGen Inc. today announced t€∑•hat it has entered into a d"←÷rug discovery research collaborat≥γ×ion with Galapagos NV to identifλ£≠≤y potential small molec •↕δule leads against targets of interest to λ₽πGalapagos NV. In this cσ←ollaboration, HitGen will appΩ✔™ ly its technology platform, based on DNA-enc₹Ωoded library design, synthesis and interroga≥&≤σtion, to discover no↓®vel leads. Under the terms of t≈☆÷he agreement, HitGen will receive an undiscl↑×osed upfront payment and willΩ©★♠ be eligible for milestone payment€$'s from Galapagos NV.“We are delighted to enteσ☆α>r this collaboration with Galapagos NV, a l♦'σ≥eading biotechnology company, specializing in th∑£e discovery and development of β♦small molecule medicines with novel moσ∞☆§des of action. We believe the col∏€laboration reinforces the role of HitGen♥∑’s platform in the rapidly d↔∏ eveloping field of DNA-encoded c§↑hemistry. We will work closely ₹★✘with Galapagos NV scientists t®™←o generate new small-molecule '©lead compounds for their research programs to hel→↔$p bring transformative medicines to patγ∞£ients,” said Dr. Jin Li, Chairman of the Board aαλnd Chief Executive O♠×fficer of HitGen.“We lo"∞ ok forward to working with HitGen an& ≥÷d tap into their established DEL techno ₩logy platform to complement our↓π£ internal screening and drug discovery techn♥δσ≥ologies.” said Romain Gosmini, Director Medicina✔€l Chemistry at Galapago₹&s.information source:pharma focus AsiaThe o ×$riginal link:https:htt$×✔ps://www.pharmafocusasia.com/news/hitgen-entersγ↕-into-dna-encoded-library-bas£≠ed-drug-discovery-research-collaborat§≠$ion-with-galapagos-nv2019 Asia-pacific pha∏≤§✘rma IP Leader Summit: http://en. ©zenseegroup.com/p/510934/&•§€γnbsp;will be held in Beijing≤®≠ on November 14-15, and will a ∑ttract more than 500 industry expertεσs from domestic and foreign pharmaceutical cσ¶✘ompanies, biotechnology companies, govern≠₩¶ments, associations, law firms, inte©↔•llectual property agents and other ™"<δcompanies to attend.Offi→₹cial registration and consultation channels:÷₹♠∏Contact：AnnPhone: 021-65650305Email：Marketi¥×αng@zenseegroup.comhttp://en.zens±γeegroup.com/p/510934 -
1017
WindMIL Therapeutics and University of Californi₹ ©a, Irvine Announce Collaboration to Colle±>γct Bone Marrow from Pa λ'tients with Gliomas
WindMIL Therapeutics and×∑ University of California, Irvine Announce δ ÷©Collaboration to Collect Bone→≠' Marrow from Patients with GliomasWEDNESDAβ×←£Y, OCTOBER 16, 2019WindMIL Therapeutics §βand the University of California, Irvine (UCI) λ₽today announced that the f ∑∏¶irst patients have been identified in ¶φ↑<an investigator-sponsored study for th¥←₽e collection of bone marrow from∏≥≤ patients with gliomaε±s. The study will evaluat"✘÷e generating marrow infiltrating✔≠ lymphocytes (MILs™) for these patientα$s through WindMIL’s proprietary ce≤✘π∏llular activation and expansion process. T♠≥he study is being conducted aα ✘t UCI.“Patients suffering with glioblasto∏$σγma are in great need of new, prom©♠•ising treatments that might advance tγΩ♦he current standard of care,” s™←&aid Daniela A. Bota, MD, ↔&₹ PhD, director of the UCI Health Comprehensive ₽ε ¶Brain Tumor Program, seni<γ✘∏or associate dean for₽♠→ clinical research, $'UCI School of Medicine and clinical δ±'director, UCI Sue & Bill Gross Stem δ↓πCell Research Center. “The Uni≠€versity of California, Irvine is exc¥₩∑ited to play a key role↑φ↔' in research that ma ↔y lead to a clinical trial that enlists the ¶€immune system in novel ways to fight this te€¶✔rrible disease.”Gliomas are the mo'st common of the maligφ©nant brain tumors. Gli ↓εoblastoma, the most common glioma, has a f←☆εive-year survival of less than 5 percent. Additio©¥nal treatment options are urgently n♥>¶eeded for these patients. Adoptive © ≥©immunotherapy is a possible approach for gliomas ∞δ± and the use of MILs, a cell therapy that is natφ&&urally tumor-specific β, is one such treatment option.The ∑•←₹bone marrow is a unique niche in the immune©©♠π system to which antigen-experienced memory T c≤®÷ells traffic and are then m♣☆δaintained. WindMIL has dδ¥eveloped a proprietary process to sel∞♥☆ect, activate and expand these memory T cells int×♥¶≤o MILs. Because memoβ ♣×ry T cells in bone marrow occur as a re±&♠sult of the immune system’s r∞π↔ecognition of tumor antigens, MILs are spec∑ ±ifically suited for adoptive cellular immuno¶™therapy and are able to ♥≠←¥directly eradicate or facilitate erad€☆γication of each patient’s unique cancer. WindMIL ≈σis currently studying MILs in↑ ↔ multiple myeloma, non-small cel$∑l lung cancer and squamous cell carcinom←a of the head and neck, and plans to ★♣λexpand into other solid tumors∞÷≥.“WindMIL is looking forward t®≠γo working with the University of Ca≠"₽™lifornia, Irvine on this exciting project and i'≈s optimistic that MILs may offer the pot↑₽ential to help patients with these hard-to-tδ$Ωreat diseases,” said Monil Shah, PharmDλ•, MBA, Chief Development Officer at WindMIL.infoφσrmation source:pharma$↓∑ focus AsiaThe originβ≥✔÷al link:https://www.pharmafocusasia.com/ne✘↑÷ws/windmil-therapeutics-and-university-of-califβ♣ornia-irvine-announce-collπββaboration-to-collect-bone-marrow-from-p"™atients-with-gliomas201Ω®₹₹9 Asia-pacific pharma ♣↔ IP Leader Summit: http://en.zens☆★eegroup.com/p/510934/will be held in Beij≥£ing on November 14-15, and ¥♦will attract more than 500 indusφφtry experts from domestic and ÷ foreign pharmaceutical companies, biotech↑✘nology companies, go ©vernments, associations, law firms, intellecε&∞tual property agents and other companies to at÷πδ tend.Official registration and cons≠&≤Ωultation channels:Contact：AnnPhone: 021-6≥ 5650305Email：Marketi÷γ↕ ng@zenseegroup.comhttp://en.✔↕'zenseegroup.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Th♦Ωerapeutics Announce Licen₹≤÷♦se Agreement to Advance Companies’ Respective Ceα↑₹•ll Therapy Programs in Oncology
CRISPR Therapeutics and KSQ Therapeutics Announ←↓<ce License Agreement to Advance Companies’ RΩ↔espective Cell Therapy Programs in Onc☆'ologyWEDNESDAY, OCTOBER ₹ 16, 2019CRISPR Therapeutics, a biopharm✔Ω§aceutical company focused on creating≤≠π transformative gene-based medicines for ↓♥αserious diseases, and KSQ✘♠ Therapeutics, a biotechnology co βmpany using CRISPR technology to enable the compa¥∏ny’s powerful drug discovery enΩδ€♣gine to achieve higher probabilities of success↑ε in drug development, today announced a license a§ε€×greement whereby CRISPR ♣™Therapeutics will gain acc♣ ♠ess to KSQ intellectual propert¶✔y (IP) for editing certain novel gene ∑☆targets in its allogeneic oncology cell therap♣♣¶y programs, and KSQ will gain access to ₽∑CRISPR Therapeutics’ IP for edi ≥★ting novel gene targets ide€₩¶£ntified by KSQ as part of its curr↓÷₩∏ent and future eTILTM (engineered tumor iδ¶nfiltrating lymphocyte) cell programs. The ✔ financial terms of the agreement are not <being disclosed.“We ar€∑®e thrilled to gain access to CRISPR The$✘>rapeutics’ foundational IP estate through th∑₩↕is agreement,” said David Mee䮀ker, M.D., Chief Executive O §&'fficer at KSQ Therapeutics. “Our eTILTMδ↓ programs involve editing ge©∑ne targets in human TILs¥¥δ that were discovered at KSQ by applying o β✔ur proprietary CRISPRomics® approach to immune ↓≠" cells in multiple in vivo models. This a§γgreement clears an important path f¥§©or us to be able to bring these progr§™ams through development and com↕€♦ mercialization, leveraging CRI§&¥☆SPR Therapeutics’ pr£ oprietary editing technolog ®∑y.”The gene targets within the scope of the lice♦¥nse agreement were id♦ entified using KSQ’s prop®€rietary CRISPRomics® drug discovery engine, wh₽↓ich allows genome-scale, in ≥π vivo validated, unbiased drug discovery. Th±♥☆ese specific targets were uncovered in screen♥<s to identify genetic edits that cou♥↕♦ld enhance the functionality and quality of adop¥ε✘tive cell therapies in oncology.“KSQ has bui↓☆δ≠lt an industry-leading platform to screen for novδ♣₩¥el gene targets using its techno•≥∞ logy, and has identi±>fied a group of targets that could hel∞✘p unlock the full potential of adoptive cell th±α↑erapy in oncology,” said Samart↓×'h Kulkarni, Ph.D., Chief↕≠♠ Executive Officer at CRISPR Therapeutics. “As a <→ result of this licen≈×se agreement, CRISPR Therapeutic€≠×s will have the opportunity to bring these ₩£novel targets into our leading allogeneic CAR₽₩"-T development platform to fu✘δrther strengthen our future p£♥rograms in this important therapeut€±↑ic area.”information source:pharm¥✔↕a focus AsiaThe origi >♥nal link:https:https://www♠ε .pharmafocusasia.com/news/crispr-therapeutic≤←¥↕s-and-ksq-therapeutics-announce-licen★se-agreement-to-advance-compani±✘es-respective-cell-therapy-programs-in-oncol<§ogy2019 Asia-pacific pharma IP Lead&♦✘£er Summit: http://en.zenseegroup®♦★∞.com/p/510934/ will be held in&nbs←δp;Beijing on November 14σφ-15, and will attract more than 500 industry ex<→perts from domestic and foreign pharmaceuti★Ω€cal companies, biotechnolog•≤±&y companies, governments, &§•∏associations, law firms, intellectual₽α property agents and other↕ • companies to attend.Official Ω→registration and consultation channels:Co£®α≤ntact：AnnPhone: 021-65650305Email：Marketing@zenδ©₹®seegroup.comhttp://en.zenseegroup.com/p/51∞Ω→0934/ -
1015
Shionogi enters into a new li←☆≤cense agreement and research coll•™"aboration for the treatment of myc↔σ obacterial diseases with Hsiri The×↔↕πrapeutics, Inc.
Shionogi enters into a new li¶≠cense agreement and research collaboration for¥∑ the treatment of mycobacterial diseases§ with Hsiri Therapeutics, Inc.M←'ONDAY, OCTOBER 14, 2019Shionogi & Co.↕→₹, Ltd. today announced that it ha$€₹βs entered into a new licen<≤←se agreement with Hsiri Therapeutics, ♣∑>Inc. (Head Office: Media, PA, USA; Presidenπ≠≤t and CEO: William Claypool, M.D.; φ>hereafter "Hsiri") regarding∏♣ a collaborative researcα♠h and development program to discover and∞π♥ develop additional novel therapeutics for no≥™εn-tuberculous mycobacterial (NTM) diseasσ es and tuberculosis (TB). Th↔✘ is new collaboration will include technology☆₩≠ that complements Shionogi's e>₩"arlier collaboration arrangemen←↔↓t with Hsiri.The new technology π to be licensed from Hsiri has a novel ♣₩δmechanism of action, will be c >✘'omplementary to Shionogi's c♦✘urrent research with • $↑Hsiri, and is anticipated to be m™'₩ore effective than current ¶←★therapies for mycobacterial infecti'∞±ons. Shionogi's strength in small molecule drug ↑♣γdiscovery and developme¶€εnt in the antibacterialα→✔ area will support develop☆• ♣ment of Hsiri's innovative therapeutics in t£©his collaborative program. ×♦Under the terms of this agreement, Sh•±×©ionogi will have exclusive ∏≤worldwide rights to dπ$evelop, manufacture, and comλ∞β↔mercialize the compounds generated from th★¥≠e collaboration. Hsiri ✔will receive an upfront license fe♠¶e, potential development milestones, and r♠&≤oyalty payments based on sales from Shi÷¥↔¶onogi.It is reported that the number of p&'atients suffering from NTM d≤β$iseases has been increasing, especially in d©♥eveloped countries, in recent years. There is a m₽edical need to develop ®'>novel anti-NTM drugs because ofπ≥< the long duration of ¶ •treatment and insufficient treatment outcom e of current therapeutics. TB is one ∞ Ω♠of the three major infectious disease★≥→s in the world, and new cases of TB are estimated to ♦→γbe 10.4 million/year. Multidrug-re≠↑$≥sistant TB (MDR-TB) and e★ xtensively drug-resistant TB (XDR-TB) have bec"σ™✘ome a major public health concern, and novel d®σrugs for MDR-TB and XDR-TB are anticipa ≠÷∑ted.Shionogi's research an<§§©d development targets infectious dise®>"ase as one of its priority areas, and₩₩↓ Shionogi have positioned "protecting people from↑λ the threat of infectious dise®€ases" as one of its soci✔π'al mission targets. Through this coop&•δ$eration, Shionogi strives cε"onstantly to bring forth innovative drugs f←αor the treatment of in$↕β₽fectious diseases, t•φ↔ o protect the health of patients we serve.informa↕♦γ tion source:pharma focus AsiaThe orig≥€"inal link:https:https:https://ww©§↑ w.pharmafocusasia.co∞δ≥<m/news/shionogi-enters-into-a-new-lβ¶₹"icense-agreement-and-research-collaborat¶≤∞ion-for-the-treatment-of-myco$ε€bacterial-diseases-with-hsiri-therape ¶δutics-inc2019 Asia-pacific pharma IP Leade★→₹r Summit: http://en.zenseegroup.com/p/5&™10934/ will be held in ε ¶Beijing o₹€n November 14-15, and will attract more ★✘ εthan 500 industry experts from domestic ÷↔and foreign pharmaceutical c≥₹ompanies, biotechnology comp☆π≥®anies, governments, associations, law fi£¶rms, intellectual property agen✔↔ts and other companies $≈®to attend.Official registration and consultati♣Ωon channels:Contact：φ∏> AnnPhone: 021-65650305Email：Market"★'≈ing@zenseegroup.comhttp://en.zens ≥eegroup.com/p/510934/ -
1014
Advaxis and UCLA Enter Collabora≈™★<tion for Glioblastoma Immu£ε♣↓notherapy Discovery R✘★esearch
Advaxis and UCLA Enter Collaboration for↑φ✔ Glioblastoma Immunotherapy Disco πvery ResearchFRIDAY, OCTO£©♣φBER 11, 2019Advaxis, Inc., ≥™≤a clinical-stage biotechnology compa∞φ€™ny focused on the discovery, development and com &mercialization of immunot€'φherapy products, today announced a researc♥∞h collaboration agreement wit☆®h the University of California Los Angeles (U≈πCLA) to conduct preclin∞εδical studies evaluating the Comδ♥πpany’s Lm technology in mouse tumor≠ ♣λ models of glioblastoma multiforme (GBM). Specifi><cally, the collaboratio ≤n with Dr. Vaithi Arumugaswami’s group at UCLA’s ¥↑φ↕Department of Molecular and M✔™♦Ωedical Pharmacology will investigπ☆≈ate anti-tumor immunit ÷σσy and anti-tumor responses generated by Lm vacci$✘₩×nes that express diverse gl<¶<λioblastoma neoantigens.“We are excited that Dr. ♠☆Arumugaswami and his colleag↕✔¥ues at UCLA will investigat€∞e the potential of our Lm tec≤"hnology platform in GBM, one "¶of the deadliest can↔≤πcers,” said Andres Gutierrez, Executive Vice Pr→×♣esident and Chief Medical Officer of Adv↑Ω✔axis. “Contrary to other tumor types≠β, GBM has not seen much success in targetin÷↕✔♥g by immunotherapeutic agents¥β due to a low tumor mutation burden, h§♥↑♠igh tumor heterogeneity and presence of₽≠ the blood brain barrier, among other ✘ factors. Hence, Dr. Arumuga★☆÷swami’s characterization of★σ the neoantigen landscape απ≥and immune responses to Lm- constr<★σ ucts may lead to the development of &☆ novel therapies with clinical&™÷α activity in this elusive cancer.”inf×'₽ormation source:pharma focus AsiaεβThe original link:https:https:https://www.phar↕₽₽♠mafocusasia.com/news/advaxis-and-&ε¥ucla-enter-collaborati✘÷on-for-glioblastoma-immunotherapy-discovery-res<↓¶earch2019 Asia-pacific pharma IP Leader Summπ≤it: http://en.zenseegroup.com/p/510934/will be h£÷eld in Beijing&n☆§bsp; on Nove↕δ←mber 14-15, and will attract more tφ✔han 500 industry exp•¥≈erts from domestic and foreign←≈" pharmaceutical compan∑'ies, biotechnology companies, government✘×↑©s, associations, law firms, inte∞£ ♥llectual property agents and other compaα$nies to attend.Officiπππal registration and consultation chann÷♣els:Contact：AnnPhone: 021-65650305Email：Mark∑§φ<eting@zenseegroup.comhttp://en.zens<✔eegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016